FOLD vs JNJ

Amicus Therapeutics (FOLD) was acquired by BioMarin Pharmaceutical for $14.50 cash per share on April 27, 2026, leading to its delisting from Nasdaq on April 28, 2026. This fundamental change means FOLD no longer exists as an independent publicly traded entity. Consequently, it offers no future investment potential, let alone a '10x growth potential,' for new or existing investors, as shares are n...

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...